Golimumab
Golimumab
Immunoglobulin G1, anti-(human tumor necrosis factor α)(human monoclonal CNTO 148 γ1-chain), disulfide with human monoclonal CNTO 148 κ-chain, dimer
Stoffgruppe
Immunsuppressivum (TNF-alpha-Inhibitor)
Halbwertszeit
12 ± 3 Tage